Clinical Trials
16 trialsNCT02158858 2026-06-04
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT06135415 2026-03-25
TirbAKare
Almirall, S.A.
Phase 3 Completed
NCT06982313 2026-03-11
Babytam long
Ente Ospedaliero Ospedali Galliera
Completed
NCT04950608 2026-02-17
PATH
Dana-Farber Cancer Institute
Phase 2 Completed
NCT07112729 2026-02-03
SMS
Chang Gung University
Phase NA Completed
NCT01302834 2026-01-12
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00625066 2025-12-17
Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy
Vanderbilt University Medical Center
Completed
NCT05407311 2025-11-17
SABRE
Clarity Pharmaceuticals Ltd
Phase 2 Completed
NCT06030427 2025-10-24
Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors
Mayo Clinic
Phase NA Completed
NCT03874754 2025-10-14
iHBE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed
NCT00769587 2025-09-22
Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Centre Hospitalier Universitaire, Amiens
Completed
NCT06165614 2025-08-19
Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT06372236 2025-08-12
UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors
Peking University
Phase 1 Completed
NCT05997342 2025-08-11
A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT01837693 2025-06-26
NTCC2
Azienda USL Reggio Emilia - IRCCS
Phase NA Completed
NCT05040152 2025-06-17
HERO
Ohio State University Comprehensive Cancer Center
Phase NA Completed